Patient Screening
Patient selection is the foundation of safe, considered regenerative care. Before any protocol is recommended, our team conducts a thorough clinical evaluation — reviewing your history, labs, imaging, and goals to determine candidacy and design a plan tailored to you.
Patient Screening Essentials — Tap image to view full size
What We Review
Every consultation includes a structured review designed to determine whether a regenerative approach is appropriate for you — and whether established alternatives may be more suitable.
Patient selection is a primary determinant of safety and outcome. We review source tissue quality, metabolic health, immune status, and donor-material compliance based on whether a protocol is autologous or allogenic.
Glycemic control, smoking history, BMI, and baseline labs (CBC, CMP) — together with appropriate imaging — help us understand the environment in which any biologic protocol is being considered.
Active systemic infection, recent malignancy, or uncontrolled chronic illness are reviewed as part of standard candidacy evaluation. Psychosocial readiness and post-procedure support are also discussed during consultation.
Products considered in our protocols are reviewed against applicable FDA cGMP/GTP standards and 21 CFR Part 1271 expectations. We discuss regulatory status openly during consultation.
